Apollo Health Ventures

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

Refoxy Pharma develops therapeutic medicines intended to treat age-related diseases and promote healthy longevity. It researches proteins that regulate multiple genes involved in stress resistance and metabolism and develops novel modulators of a central stress response pathway to influence aging through genetics, with the aim of extending the years of healthy living for patients.

Booster Therapeutics is a biotechnology company focused on developing drug modalities to regulate cellular homeostasis and eliminate toxic accumulations. Its primary goal is to reinstate balance within cells, enabling the prevention and treatment of diseases associated with aging.

Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. It focuses on developing innovative therapeutics for rare and age-related diseases by targeting molecular pathways that address underlying causes of disease initiation and progression.

Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Auron Therapeutics is a biotechnology company focused on cancer therapy development that seeks to change the paradigm from tumor cell killing to differentiation therapy, aiming to transform malignant cells into normal functioning cells by reactivating endogenous cellular programs. The company uses platforms that integrate large-omic datasets and miniaturized high-throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. This approach is designed to advance therapeutic candidates for cancer across areas of unmet medical need and to support the development of transformative medicines. Auron Therapeutics was founded in 2018 and is based in Wellesley, Massachusetts.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Bloom Science is a clinical-stage biopharmaceutical company focused on developing microbiome-based therapeutics for neurological disorders. It employs a gut-brain axis approach through its IrisRx platform to discover and design medicines from gut microbes using synthetic biology, aiming for novel biology and improved safety profiles. The company seeks to translate the therapeutic benefits associated with the ketogenic diet into medicines that treat epilepsy and other central nervous system conditions. Its pipeline encompasses therapies for Dravet syndrome and other rare epilepsies, as well as Amyotrophic Lateral Sclerosis and other neurodegenerative and cognitive disorders. Bloom Science pursues translational research to advance microbe-based therapeutics that address unmet needs in neurology. The company is headquartered in San Diego, California.

Ochre Bio is a biotechnology company founded in 2019 and headquartered in Oxford, United Kingdom. The firm focuses on developing genomic medicines that rejuvenate donor livers before transplantation, aiming to expand the supply of healthy organs for patients. By using genomics to identify and silence over‑active genes that drive liver disease, Ochre Bio tests novel RNA‑based therapies directly in discarded donor livers maintained on machine‑based perfusion systems. This approach allows the company to evaluate treatments in a human organ context, reducing complications such as cirrhosis and improving transplant outcomes. With more than fifteen years of liver genomics research experience, Ochre Bio leverages deep phenotyping and advanced therapeutic modalities to create a pipeline of medicines for liver and liver‑mediated conditions.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. It focuses on developing innovative therapeutics for rare and age-related diseases by targeting molecular pathways that address underlying causes of disease initiation and progression.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Cleara Biotech B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on developing innovative therapeutics to selectively eliminate senescent and senescent-like cancer cells. The company specializes in creating FOXO4-based anti-senescence drugs aimed at addressing chemotoxicity and combating therapy-resistant cancer cells. Cleara Biotech's research targets a crucial aspect of cancer treatment by aiming to enhance the effectiveness of therapies and improve patient outcomes through the targeted removal of problematic cell populations.

Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. It focuses on developing innovative therapeutics for rare and age-related diseases by targeting molecular pathways that address underlying causes of disease initiation and progression.

HAYA Therapeutics develops RNA-based therapeutics focused on treating fibrotic diseases. Its precision medicines target specific regulators of fibrosis in tissues like the heart, aiming to block fibrosis progression and treat associated conditions safely and effectively.

Therini Bio is a biotechnology company focused on developing fibrin-targeting therapies for treating inflammatory neurological and retinal diseases. Its therapeutics are based on unique insights into the role of fibrin in driving chronic innate immune activation, addressing high unmet needs in various diseases.